{"product_id":"harvard-21st-biennial-course-in-urologic","title":"Harvard 21st Biennial Course in Urologic Oncology 2022","description":"\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003ch2\u003eHarvard 21st Biennial Course in Urologic Oncology 2022\u003c\/h2\u003e\n\u003cbr\u003eBiennial Course in Urologic Oncology\u003cbr\u003e\u003cbr\u003e\u003cspan style=\"color: #1b1919; font-size: 24px;\"\u003e2022 Course Overview\u003c\/span\u003e\n\u003cbr\u003e\u003cdiv aria-labelledby=\"tab-title-description\" class=\"woocommerce-Tabs-panel woocommerce-Tabs-panel--description panel entry-content active\" id=\"tab-description\" role=\"tabpanel\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\n\u003cbr\u003e\u003cbr\u003eBiennial Course in Urologic Oncology Beginning in 1982, the multidisciplinary Urologic Cancer Course was designed as a biennial course bringing together expertise from all the Harvard teaching hospitals in conjunction with invited world class experts in urologic oncology, medical oncology, and radiation oncology. Dr Marc B. Garnick led the course from 1982 to 1996 at which time Dr Jerome P. Richie assumed the leadership until 2014. Dr. Phillip W. Kantoff then led the course and subsequently in 2016 Dr Adam Kibel, Dr Toni Choueiri and Dr. Anthony V D’Amico co-led the course.\u003cbr\u003e\u003cbr\u003eBiennial Course in Urologic Oncology In 2022 our keynotes will be delivered by 2 internationally renowned scholars. Dr. George Daley Dean of Harvard Medical School and Dr. Lindsey Baden Principle Investigator of the Covid Moderna Trial.\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"variant-1\"\u003eWho Should Attend\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003ePrimary Care Physicians\u003c\/li\u003e\n\u003cli\u003eSpecialty Physicians\u003c\/li\u003e\n\u003cli\u003eNurses\u003c\/li\u003e\n\u003cli\u003eNurse Practitioners\u003c\/li\u003e\n\u003cli\u003ePharmacists\u003c\/li\u003e\n\u003cli\u003ePhysician Assistants\u003c\/li\u003e\n\u003cli\u003ePsychologists\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 class=\"variant-1\"\u003eLearning Objectives\u003c\/h3\u003e\n\u003cbr\u003eUpon completion of this activity, participants will be able to:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eDemonstrate the optimal management of oligometastatic prostate, bladder, renal cancer\u003c\/li\u003e\n\u003cli\u003eExplain the role of immunotherapy in the management of bladder, prostate and renal cancer\u003c\/li\u003e\n\u003cli\u003eDetermine how to incorporate genomic classifiers, multiple parametric MRI, and clinical parameters into selecting optimal patients with prostate cancer for active surveillance or other definitive management approaches\u003c\/li\u003e\n\u003cli\u003eApply Level 1 evidence on the use of novel treatment paradigms and updated surveillance options for patients with prostate, renal, bladder, or testicular cancer\u003c\/li\u003e\n\u003cli\u003eApply novel minimally invasive treatments for GU malignancies including prostate, bladder and kidney cancer\u003c\/li\u003e\n\u003cli\u003eUse multiparametric MRI, fusion biopsy and novel markers in men at risk for prostate cancer\u003c\/li\u003e\n\u003cli\u003eBiennial Course in Urologic Oncology\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"bundle--paragraph_component paragraph paragraph--type--paragraph-component paragraph--view-mode--default\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\n\u003ch2 class=\"component-title field__item\"\u003e2022 Agenda\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\n\u003ch3 class=\"variant-1\"\u003eInformation for the 2023 course is not yet available.\u003c\/h3\u003e\n\u003cbr\u003eBiennial Course in Urologic Oncology\u003cbr\u003e\u003cbr\u003eAll agenda sessions are in Eastern Time.\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"bundle--hms_program_details_list paragraph paragraph--type--hms-program-details-list paragraph--view-mode--default open\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12\"\u003e\n\u003cdiv class=\"hms-program-details-list--items field-wrapper field field--name-field-hms-pdl-item field--type-entity-reference-revisions field--label-hidden field__items\"\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cstrong\u003eTHURSDAY, OCTOBER 13, 2022\u003c\/strong\u003e\n\u003cbr\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e7:15 – 8:00 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eRegistration\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e8:00 – 8:05 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eWelcome\u003cbr\u003eAnthony D’Amico\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e8:05 – 8:20 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eEpidemiology and Genetics\u003cbr\u003eLorelei Mucci\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e8:20 – 8:35 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eScreening in 2022: Role of PSA and Novel Biomakers\u003cbr\u003eAdam Kibel\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e8:35 – 8:50 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eAdvanced in Multiparametric MRI for Diagnosis and Staging\u003cbr\u003eClare Tempany\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e8:50 – 9:05 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eInterpreting Prostrate Biopsy Reports\u003cbr\u003eMichelle Hirsch\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e9:05 – 9:30 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eExpert Panel: Screening and Diagnosis\u003cbr\u003eModerator: Anthony D’Amico\u003cbr\u003eSpeakers: Michelle Hirsch, Adam Kibel, Lorelei Mucci and Clare Tempany\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e9:30 – 10:00 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eBreak\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e10:00 – 10:15 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eFocal Ablation and Active Surveillance in Intermediate Risk Disease\u003cbr\u003eAlexander Cole\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e10:15 – 10:30 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eRadical Prostatectomy in Intermediate Risk Disease\u003cbr\u003eQuoc-Dien Trin\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e10:30 AM – 10:45 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eHypofractionation and ADT use in Intermediate Risk Prostate Cancer\u003cbr\u003eNeil Martin\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e10:45 – 11:00 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eMRI Guided Radiation therapy\u003cbr\u003eJonathan Leeman\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e11:00 – 11:15 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eOptimizing Systemic Therapy in the Management of Intermediate and High-Risk Prostate Cancer\u003cbr\u003eAnthony D’Amico\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e11:15 – 11:30 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eNovel Approaches in the Preoperative Setting for the High-Risk Patient\u003cbr\u003eMary-Ellen Taplin\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e11:30 – 11:45 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eBiomarker Based Clinical Trials and Prostate Cancer\u003cbr\u003eMartin Gleave\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e11:45 AM – 12:15 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eExpert Panel: Patient Selection\u003cbr\u003eModerator: Anthony D’Amico\u003cbr\u003eSpeakers: Alexander Cole, Martin Gleave, Jonathan Leeman, Neil Martin, Mary-Ellen Taplin, Quoc-Dien Trinh\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e12:15 – 1:00 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eLunch\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e1:00 – 1:15 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003ePET Imaging in the PSA Recurrent Setting-Diagnostics\u003cbr\u003eHeather Jacene\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e1:15 – 1:30 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eTreatment of Oligo Metastatic Disease, Integration of Surgery\u003cbr\u003eSpeaker: Martin Gleave\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e1:30 – 1:45 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eTreatment of Oligo Metastatic Disease, Integration of Radiation\u003cbr\u003ePaul Nguyen\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e1:45 – 2:00 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003ePrecision Medicine in Prostate Cancer\u003cbr\u003eHimisha Beltran\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e2:00 – 2:30 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eExpert Panel: Updates in Diagnostics and Special Populations\u003cbr\u003eModerator: Adam Kibel\u003cbr\u003eSpeakers: Himisha Beltran, Martin Gleave, Heather Jacene and Paul Nguyen\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e2:30 – 2:45 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eBreak\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e2:45 – 3:00 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eAdjuvant versus Salvage Radiation\u003cbr\u003eAnthony D’Amico\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e3:00 – 3:15 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eManagement of the Rising PSA in the Patient with M0 Castrate Sensitive Prostate Cancer\u003cbr\u003eCharles Ryan\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e3:15 – 3:30 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eManagement of Advanced Prostate Cancer in the Elderly\u003cbr\u003eAlicia Morgans\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e3:30 – 3:45 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eSurvivorship and Side effects of ADT\u003cbr\u003ePhil Saylor\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e3:45 – 4:00 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eManagement of Side Effects of Radical Prostatectomy in the Denovo and Recurrent Settings\u003cbr\u003ePeter Chang\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e4:00 – 4:15 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eManagement of Side Effects of Radiation Therapy in the Denovo and Recurrent Settings\u003cbr\u003eDaniel Schmidt\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e4:15 – 4:30 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eManagement of the Side Effects of Non-ADT Systemic Treatment for Prostate Cancer\u003cbr\u003eMark Pomerantz\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e4:30 – 5:00 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eExpert Panel: Management of Treatment Related Toxicity and Recurrent Disease\u003cbr\u003eModerator: Adam Kibel\u003cbr\u003eSpeakers: Peter Chang, Anthony D’Amico, Alicia Morgans, Mark Pomerantz, Charles Ryan, Phil Saylor and Daniel Schmidt\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"bundle--hms_program_details_list paragraph paragraph--type--hms-program-details-list paragraph--view-mode--default open\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12\"\u003e\n\u003cdiv class=\"hms-program-details-list--items field-wrapper field field--name-field-hms-pdl-item field--type-entity-reference-revisions field--label-hidden field__items\"\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 hms-program-details-list--term\"\u003e\u003cstrong\u003eFRIDAY, OCTOBER 14, 2022\u003c\/strong\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e8:00 AM – 8:15 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eManagement of the Rising PSA in the Patient with M0 Castrate Resistant Prostate Cancer\u003cbr\u003eAtish Choudhury\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e8:15 – 8:30 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003ePersonalizing Treatment Selection in Metastatic, Hormone-sensitive Prostate Cancer\u003cbr\u003eChristopher Sweeney\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e8:30 – 8:45 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eImmunotherapy for Prostate Cancer\u003cbr\u003eXiao Wei\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e8:45 – 9:00 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eNovel Androgen Receptor Targeted therapy of Castrate Resistant M1 PC\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e9:00 – 9:15 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003ePET Imaging in the PSA Recurrent Setting – Therapeutics\u003cbr\u003ePraful Ravi\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e9:15 – 9:45 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eExpert Panel: Management of Metastatic Prostate Cancer\u003cbr\u003eModerator: Glenn Bubley\u003cbr\u003eSpeakers: Atish Choudhury, Praful Ravi, Charles Ryan, Christopher Sweeney, and Xiao Wei\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e9:45 – 10:15 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eBreak\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e10:15 – 10:45 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eSpecial Lecture, Kidney Development and Wilms Tumor: Prospects for Regeneration\u003cbr\u003eGeorge Daley\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e10:45 – 11:00 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eRole of Biomarkers in Diagnosis and Follow-up\u003cbr\u003eAdam Feldman\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e11:00 – 11:15 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eManagement of Superficial Bladder Cancer\u003cbr\u003eAngela Smith\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e11:15 – 11:30 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eGenomics and its Role in the Management of Bladder Cancer\u003cbr\u003eJoaquim Bellmunt\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e11:30 – 11:45 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eManagement of Upper Tract Disease\u003cbr\u003eMatthew Mossanen\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e11:45 AM – 12:00 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eUrinary Diversion after Cystectomy, Choices and Outcomes\u003cbr\u003eAndrew Wagner\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e12:00 – 12:15 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eLymph Node Dissection and Approaches to Radical Cystectomy\u003cbr\u003eMark Preston\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e12:15 – 1:00 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eLunch\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e1:00 – 2:00 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eJudah Folkman Lecture: Emerging Strategies in the Fight Against Covid-19\u003cbr\u003eLindsey Baden\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e2:00 – 2:15 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eGenomic Predictors of Response to Chemotherapy\u003cbr\u003eKent Mouw\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e2:15 – 2:30 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003ePersonalizing Bladder Cancer Treatment in Variant Histology\u003cbr\u003eAngela Smith\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e2:30 – 2:45 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eNeoadjuvant and Adjuvant Chemotherapy\u003cbr\u003eRichard Lee\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e2:45 – 3:00 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eBladder Sparing Approaches\u003cbr\u003eJason Efstathiou\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e3:00 – 3:15 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eChemo and Immunotherapy for Advanced Urothelial Cancer\u003cbr\u003eJoaquim Bellmunt\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e3:15 – 3:45 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eExpert Panel: Bladder Cancer\u003cbr\u003eModerator: Adam Kibel\u003cbr\u003eSpeakers: Joaquim Bellmunt, Jason Efstathiou, Adam Feldman, Richard Lee,  Kent Mouw, Matthew Mossanen, Mark Preston, Angela Smith and Andrew Wagner\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e3:45 PM – 4:00 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eBreak\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e4:00 – 4:15 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eManagement of Seminoma\u003cbr\u003eAlok Tewari\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e4:15 – 4:30 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eManagement of Stage I non-seminoma\u003cbr\u003eTimothy Clinton\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e4:30 – 4:45 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eUpdates in Radiation Therapy in Testis Cancer\u003cbr\u003eSophia Kamran\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e4:45 – 5:00 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eManagement of Advanced Disease-Chemotherapy\u003cbr\u003eChristopher Sweeney\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e5:00 – 5:15 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eEmerging Role of Genomics in Testis Cancer\u003cbr\u003eEliezer Van Allen\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e5:15 – 5:45 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eExpert Panel: Testis Cancer\u003cbr\u003eModerator: Jerome Richie\u003cbr\u003eSpeakers: Timothy Clinton, Sophia Kamran, Christopher Sweeney, Alok Tewari and Eliezer Van Allen\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"bundle--hms_program_details_list paragraph paragraph--type--hms-program-details-list paragraph--view-mode--default open\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12\"\u003e\n\u003cdiv class=\"hms-program-details-list--items field-wrapper field field--name-field-hms-pdl-item field--type-entity-reference-revisions field--label-hidden field__items\"\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 hms-program-details-list--term\"\u003eSATURDAY, OCTOBER 15, 2022\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e8:00 – 8:15 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eTackling Tumor Metabolism in Renal Cell Carcinoma\u003cbr\u003eKimryn Rathmell\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e8:15 – 8:30 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eUpdated in the Pathology Classification of Renal Cell Cancer\u003cbr\u003eMichelle Hirsch\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e8:30 – 8:45 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eRole of Observation and Ablation for Small Renal Mass\u003cbr\u003eAria Olumi\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e8:45 – 9:00 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eRadical or Partial Nephrectomy: Techniques and Innovations\u003cbr\u003eSteven Chang\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e9:00 – 9:15 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eManaging the Primary when Metastatic and Metastatectomy\u003cbr\u003eKeyan Salari\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e9:15 – 9:30 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eAdjuvant Strategies in RCC\u003cbr\u003eToni Choueiri\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e9:30 – 10:00 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eBreak\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e10:00 – 10:15 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eAdvanced Disease: First Line Options\u003cbr\u003eVincent Xu\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e10:15 – 10:30 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eAdvanced Disease: Post IO Setting\u003cbr\u003eDavid McDermott\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e10:30 – 10:45 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eNon Clear Cell RCC\u003cbr\u003eBradley McGregor\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e10:45 – 11:00 AM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eNovel Targets Beyond Targeted Agents and IO Drugs\u003cbr\u003eXin Gao\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e11:00 AM – 12:00 PM\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-8 hms-program-details-list--body\"\u003e\n\u003cbr\u003e\u003cbr\u003eExpert Panel: Renal Cell Carcinoma\u003cbr\u003eModerator: Tonu Choueiri\u003cbr\u003eSpeakers: Steven Chang, Xin Gao, Michelle Hirsch, David McDermott, Bradley McGregor, Aria Olumi, Kimryn Rathmell, Keyan Salari and Vincent Xu\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cbr\u003eBiennial Course in Urologic Oncology\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954437132386,"sku":"MED-AMB03492","price":60.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/photo_2022-11-14_22-04-47-768x478-1.jpg?v=1779376689","url":"https:\/\/meducourse.com\/products\/harvard-21st-biennial-course-in-urologic","provider":"Meducourse","version":"1.0","type":"link"}